Tiziana (NASDAQ:TLSA) has what it takes to offer cancer patients non-intravenous treatment. The company has been doing a phenomenal job in the development of innovative therapeutics. Its primary focus is on inflammation, oncology, and infectious diseases. To continue influencing the market, the company wants to enhance CAR-T therapy for cancer.
The CEO, Dr. Kunwar Shailubhai, believes that this can be achieved through the use of Foralumab. Hence, the company has gone ahead to submit a patent application for the fully human anti-CD3 monoclonal antibody (mAb) reportedly a potential candidate. The patent demonstrates inventions related to improving CAR-T expansion and its administration as a single dose or in combination.
CAR-T Cell Therapies Are Generated from the Patients’ T Cells
Dr. Shailubhai says CAR-T is one of the most promising therapies. This is perhaps because the T-cells are created from a patients’ immune system. Their primary role is to hunt down and destroy cancer cells by reprogramming a chimeric antigen receptor (CAR).
There has been a notable trend of possible success from CAR-T cell therapy in the treatment of various hematological and solid cancers. There may have been high rates of relapses with the therapy, but advanced improvement can still be achieved through effective production processes.
Tiziana Is Collaborating With Sciarra Laboratories to Advance COVID-19 Treatment
Like many other companies, Tiziana has also dived into developing a possible treatment for COVID-19. Through a collaboration with Sciarra Laboratories, the company is hoping to accomplish and deliver TZLS-501, a monoclonal antibody. It is supposed to work with other drugs, and the likely method of administration is inhaling it.
The duo is also working on a unique technology, reported having the potential to send the drug directly to the lungs. The anti-IL6R mAbs has already been approved for the treatment of rheumatoid arthritis. Meanwhile, safety and toxicology studies are underway to ascertain its effectiveness in the treatment of COVID-19.
The spread of the coronavirus has been a growing threat across the globe. Hence this is a timely move, according to STC Biologics’ CEO, Dr. Magdalena Leszczyniecka.
